AgelessRx and funding an IRB-approved rapamycin trial

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Rapamycin could be the PEARL in the Longevity oyster as new human trial seeks funding.

AgelessRx is a platform that sells drugs and supplements including metformin and NAD+. The company is in the business of combating age and age-related diseases and they are seeking crowdfunding for a human trial of rapamycin, a drug that has performed positively for aging in animal trials.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2020

AgelessRX

Longevity level(s):

  • Level 4: Longevity clinical services
    Professionally qualified clinics that offer diagnosis of health and aging biomarkers; clinical guidance on lifestyle, diet and therapeutic interventions to mitigate the progression of age.
  • Level 2: Consumer diagnostics
    Companies that analyze biological samples (normally blood), lifestyle questionnaires, digital information and apply AI to identify opportunities for both clinical and lifestyle interventions to improve healthspan.
  • Level 3: Longevity biohacking
    Companies that manufacture ingredients and dietary supplements, or produce equipment such as red light therapy, cryonic chambers, and enhanced exercise equipment to maintain the metabolism and replace cellular function lost with the progression of age.

Overview

AgelessRX is a telehealth-based longevity platform offering personalized, science-backed prescription therapies and diagnostic tools designed to address the root mechanisms of aging. The company provides direct access to evidence-based treatments including metformin, NAD+ formulations, low-dose naltrexone (LDN), glutathione, GLP-1 receptor agonists, and emerging compounds such as methylene blue, targeting multiple hallmarks of aging including metabolic dysfunction, cellular senescence, and mitochondrial decline. Operating as a decentralized clinical platform, AgelessRX combines telehealth accessibility with rigorous clinical protocols to shift healthcare from reactive disease management toward proactive prevention and healthspan extension.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE